Pharmaco-economic evaluation of antibiotic therapy strategies in drg-based healthcare systems - A new approach

European Journal of Medical Research

Volumn 15, Issue 12, 2010, Pages 564-570

  Wilke, M H ^a   Grube Dr Wilke GmbH, R ^a  

^a Dr Wilke GmbH Inspiringhealth   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HUMAN; INFECTION; INTENSIVE CARE; LENGTH OF STAY; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; DELIVERY OF HEALTH CARE; DIAGNOSIS-RELATED GROUPS; ECONOMICS, PHARMACEUTICAL; LENGTH OF STAY; QUALITY-ADJUSTED LIFE YEARS;

EID: 78650581159     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. J. Boldt, Können wir uns die Fortschritte der Intensivmedizin noch leisten? Deutsche Medizinische Wochenschrift 2004; 129 (1/2): 36-40
2. Rubio-Terrés C; Garau J; Grau S; Martinez-Martinez L, Cost of bacteremia caused by methicillin-resistant vs. methicillin-susceptible Staphylococcus aureus in Spain: a retrospective cohort study., Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases; VOL: 16 (6); p. 722-8/201006/
3. Lee SY, Kotapati S, Kuti JL, Nightingale CH, Nicolau DP, Impact of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species on clinical outcomes and hospital costs: a matched cohort study, Infect Control Hosp Epidemiol. 2006 Nov;27(11):1226-32. (Pubitemid 44807467)
4. Wernitz MH, Lenz C, Veit SK. Die Bedeutung von Infektionen durch multiresistente Staphylococcus aureus für das deutsche Gesundheitswesen - The (n)ever ending story? J Pharmakol Ther 2009:18;75-82.
5. Fowler V et.al, Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus, N Engl J Med. 2006 Aug 17;355(7):653-65.
6. Resch A, Wilke M, Fink C, The cost of resistance : Incremental cost of methicillin-resistant Staphylococcus aureus (MRSA) in German hospitals. Eur J Health Econ. 2009 Jul;10(3):287-97.
7. Sculpher MJ, Pang FS, Manca A, Drummond MF, Golder S, Urdahl H, Davies LM, Eastwood A.; Generalisability in economic evaluation studies in healthcare: a review and case studies; Health Technol Assess. 2004 Dec;8(49):iii-iv, 1-192.
8. Facey K, Boivin A, Gracia J, Hansen HP, Lo Scalzo A, Mossman J, Single A; Patients' perspectives in health technology assessment: a route to robust evidence and fair deliberation; Int J Technol Assess Health Care. 2010 Jul;26(3):334-40.
9. Greenberg D, Rosen AB, Wacht O, Palmer J, Neumann PJ; A bibliometric review of cost-effectiveness analyses in the economic and medical literature: 1976-2006; Med Decis Making. 2010 May-Jun;30(3):320-7. Epub 2010 Mar 12. 10.
10. Harris AH, Hill SR, Chin G, Li JJ, Walkom E; The role of value for money in public insurance coverage decisions for drugs in Australia: a retrospective analysis 1994-2004; Med Decis Making. 2008 Sep-Oct;28(5):713-22. Epub 2008 Mar 31.
11. Heller AR, Bauer KR, Eberlein-Gonska M, Albrecht DM, Koch T; Regional anaesthesia as advantage in competition between hospitals. Strategic market analysis; Anaesthesist. 2009 May;58(5):459-68.
12. von Weizsäcker F, Maio G; Ethical insolvency?; Dtsch Med Wochenschr. 2010 Apr;135(16):819-21.
13. InEK GmbH; G-DRG System 2010; available online on: http://www.g-drg.de/ cms/index.php/G-DRG-System-2010/Fallpauschalen-Katalog/Fallpauschalen-Katalog- 2010
14. InEK GmbH; G-DRG Report-Browser 2008/2010; available online on: http://www.g-drg.de/cms/index.php/G-DRG-System-2010/Abschlussbericht-zur- Weiterentwicklungdes-G-DRG-Systems-und-Report-Browser/Report-Browser-2008-2010
15. Pick P, Busley A; MDK - Prüfungen im Krankenhaus, Oral presentation, Dt. Krankenhaustag 2009, Nov 19th 2009 www.deutscher-krankenhaustag.de/de/.../ pdf/09-Pick.pdf
16. Leister JE, Stausberg J, Comparison of cost accounting methods from different DRG systems and their effect on health care quality, Health Policy. 2005 Sep 28;74(1):46-55 (Pubitemid 41132571)